Arrowhead Pharmaceuticals, Inc. (ARWR)Healthcare | Biotechnology | Pasadena, United States | NasdaqGS
58.37 USD
+0.24
(0.413%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:15 a.m. EDT
The investment thesis here hinges entirely on the company's transition from a biotech developer to a commercial entity, a shift validated by recent Phase 3 wins and EU approvals. While the balance sheet remains fragile with negative free cash flow and a negative forward P/E, the revenue growth of 171% and the successful commercialization of assets like plozasiran suggest the business model is finally working. The market has rewarded this turnaround handsomely over the last year, yet the stock still trades at a discount to its long-term highs, leaving room for further expansion if sales accelerate. However, the lack of dividends and the high beta mean this is not a defensive play; it is a high-conviction bet on execution and market adoption. The options market is screaming for a breakout, with heavy positioning at levels well above the current price, which aligns with the 'strong buy' analyst consensus. For investors willing to tolerate the risk of a clinical trial setback or slow sales uptake, the current valuation offers a compelling entry point into a company that has seemingly cracked the code on its core technology. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.112155 |
| AutoTheta | 0.165058 |
| AutoETS | 0.165319 |
| MSTL | 0.167551 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 295.984 |
| Revenue per Share | 4.766 |
| Market Cap | 8,221,824,512 |
| Forward P/E | -11.84 |
| Beta | 1.30 |
| Profit Margins | -47.79% |
| Website | https://arrowheadpharma.com |
As of Oct. 10, 2026, 4:15 a.m. EDT: Speculators are positioning aggressively for upside, evidenced by massive open interest walls at strikes like $80, $85, $100, and $110 across multiple expirations. Call volume significantly exceeds open interest at distant strikes ($140 in Jan 2027), indicating speculative bets on a major catalyst-driven rally. Conversely, put activity is concentrated near-the-money and slightly out-of-the-money, suggesting a hedge against volatility rather than a bearish conviction. The implied volatility surface shows elevated premiums for deep out-of-the-money calls, reflecting a market pricing in binary event risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.49781883 |
| Address1 | 177 East Colorado Boulevard |
| Address2 | Suite 700 |
| All Time High | 2,925.0 |
| All Time Low | 1.2 |
| Ask | 63.16 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 2,091,870 |
| Average Daily Volume3 Month | 1,929,896 |
| Average Volume | 1,929,896 |
| Average Volume10Days | 2,091,870 |
| Beta | 1.303 |
| Bid | 55.02 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 3.298 |
| City | Pasadena |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 58.37 |
| Current Ratio | 5.899 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 60.53 |
| Day Low | 57.145 |
| Debt To Equity | 295.984 |
| Display Name | Arrowhead Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,873,600 |
| Earnings Call Timestamp Start | 1,785,873,600 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,795,550,400 |
| Earnings Timestamp Start | 1,795,550,400 |
| Ebitda | -200,635,008 |
| Ebitda Margins | -0.29968 |
| Enterprise To Ebitda | -40.008 |
| Enterprise To Revenue | 11.99 |
| Enterprise Value | 8,027,080,192 |
| Eps Current Year | -3.54004 |
| Eps Forward | -4.93101 |
| Eps Trailing Twelve Months | -2.28 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 626 304 3401 |
| Fifty Day Average | 76.7224 |
| Fifty Day Average Change | -18.352398 |
| Fifty Day Average Change Percent | -0.23920523 |
| Fifty Two Week Change Percent | 49.781883 |
| Fifty Two Week High | 95.49 |
| Fifty Two Week High Change | -37.12 |
| Fifty Two Week High Change Percent | -0.3887318 |
| Fifty Two Week Low | 36.57 |
| Fifty Two Week Low Change | 21.8 |
| Fifty Two Week Low Change Percent | 0.596117 |
| Fifty Two Week Range | 36.57 - 95.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 756,052,200,000 |
| Float Shares | 122,449,260 |
| Forward Eps | -4.93101 |
| Forward P E | -11.837332 |
| Free Cashflow | -48,628,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 711 |
| Fullday Change | 0.4600029 |
| Fullday Change Percent | 0.78808105 |
| Fullday Price | 58.83 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 669,494,976 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03657 |
| Held Percent Institutions | 0.85410005 |
| Implied Shares Outstanding | 140,857,021 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.arrowheadresearch.com/invest.html |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,321,488,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California. |
| Long Name | Arrowhead Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 8,221,824,512 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_203142 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -319,955,008 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 9,456,986,565 |
| Number Of Analyst Opinions | 13 |
| Open | 58.16 |
| Operating Cashflow | -59,055,000 |
| Operating Margins | -2.26028 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 626 304 3400 |
| Pre Market Change | 0.4600029 |
| Pre Market Change Percent | 0.78808105 |
| Pre Market Price | 58.83 |
| Pre Market Time | 1,792,055,128 |
| Previous Close | 58.13 |
| Price Eps Current Year | -16.488514 |
| Price Hint | 2 |
| Price To Book | 17.698605 |
| Price To Sales Trailing12 Months | 12.280637 |
| Profit Margins | -0.4779 |
| Quick Ratio | 5.706 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | 0.23999786 |
| Regular Market Change Percent | 0.412864 |
| Regular Market Day High | 60.53 |
| Regular Market Day Low | 57.145 |
| Regular Market Day Range | 57.145 - 60.53 |
| Regular Market Open | 58.16 |
| Regular Market Previous Close | 58.13 |
| Regular Market Price | 58.37 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 4,160,192 |
| Return On Assets | -0.08104 |
| Return On Equity | -0.55207 |
| Revenue Growth | 1.71 |
| Revenue Per Share | 4.766 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 140,857,021 |
| Shares Percent Shares Out | 0.0762 |
| Shares Short | 10,760,463 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,426,449 |
| Short Name | Arrowhead Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.106000006 |
| Short Ratio | 4.77 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARWR |
| Target High Price | 126.0 |
| Target Low Price | 74.0 |
| Target Mean Price | 107.23077 |
| Target Median Price | 104.0 |
| Total Cash | 1,597,859,968 |
| Total Cash Per Share | 11.312 |
| Total Debt | 1,379,405,056 |
| Total Revenue | 669,494,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.28 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 72.201126 |
| Two Hundred Day Average Change | -13.831127 |
| Two Hundred Day Average Change Percent | -0.19156387 |
| Type Disp | Equity |
| Volume | 4,160,192 |
| Website | https://arrowheadpharma.com |
| Zip | 91,105 |